Corrigendum: Nasal Administration of Anti-CD3 Monoclonal Antibody (Foralumab) Reduces Lung Inflammation and Blood Inflammatory Biomarkers in Mild to Moderate COVID-19 Patients: A Pilot Study

Front Immunol. 2022 Jan 12:12:815812. doi: 10.3389/fimmu.2021.815812. eCollection 2021.

Authors

Thais G Moreira¹, Kimble T F Matos², Giovana S De Paula³, Thais M M Santana³, Raquel G Da Mata³, Fernando C Pansera³, Andre S Cortina³, Marcelle G Spinola², Clare M Baecher-Allan¹, Gerson D Keppeke², Jules Jacob⁴, Vaseem Palejwala⁴, Karen Chen⁵, Saef Izzy¹, Brian C Healey¹, Rafael M Rezende¹, Rogerio A Dedivitis³, Kunwar Shailubhai⁴, Howard L Weiner¹

Affiliations

¹ Ann Romney Center for Neurologic Diseases, Department of Neurology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, United States.
² Escola Paulista de Medicina, Universidade Federal de São Paulo, São Paulo, Brazil.
³ Santa Casa de Misericordia de Santos, Santos, Brazil.
⁴ Tiziana LifeScience, Doylestown, PA, United States.
⁵ Department of Radiology, Boston Children's Hospital, Harvard Medical School, Boston, MA, United States.

Abstract

[This corrects the article DOI: 10.3389/fimmu.2021.709861.].

Keywords: COVID-19; SARS-CoV-2; anti-CD3; foralumab; immune responses.

Copyright © 2022 Moreira, Matos, De Paula, Santana, Da Mata, Pansera, Cortina, Spinola, Baecher-Allan, Keppeke, Jacob, Palejwala, Chen, Izzy, Healey, Rezende, Dedivitis, Shailubhai and Weiner.

Publication types

Published Erratum